Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul;18(4):585-591.
doi: 10.1007/s11523-023-00976-4. Epub 2023 Jun 13.

Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study

Hélène Babey  1 , Philippe Jamme  2 , Hubert Curcio  3 , Jean Baptiste Assié  4 , Remi Veillon  5 , Hélène Doubre  6 , Maurice Pérol  7 , Florian Guisier  8 , Eric Huchot  9 , Chantal Decroisette  10 , Lionel Falchero  11 , Romain Corre  12 , Alexis Cortot  2 , Christos Chouaïd  13 , Renaud Descourt  1
Affiliations

Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study

Hélène Babey et al. Target Oncol. 2023 Jul.

Abstract

Background: MET-targeted tyrosine kinase inhibitors (TKIs) demonstrated efficacy in advanced non-small cell lung cancer (aNSCLC) with MET exon14 skipping mutations (METexon14); yet, data on the management of these patients in clinical practice is sparse.

Objective: The aim of this study was to describe the management of METexon14 aNSCLC patients.

Patients and methods: This real-life, retrospective study analyzed the management of METexon14 aNSCLC. The primary endpoint was the median overall survival (mOS). Secondary endpoints were to assess investigator-progression-free survival (PFS) and mOS in different subgroups: patients treated with (a) crizotinib, regardless of treatment line; (b) anti-MET TKIs (crizotinib, tepotinib, capmatinib); and (c) immunotherapy.

Results: A total of 118 patients were included between December 2015 and January 1, 2020 in 13 centers. Median age was 73 years, 62.7% were female, 83.9% had adenocarcinoma, 92.4% at stage IV, and 27% had more than three metastatic sites. The majority of the patients (106, 89.8%) received at least one systemic treatment; 73% received at least one anti-MET TKI: crizotinib (68.6%), tepotinib (16%), capmatinib (10%). Only 10% received two anti-MET TKIs in their treatment sequences. With a median follow-up of 16 months (95% CI 13.6-29.7), mOS was 27.1 months (95% CI 18-31.4). There was no significant difference between mOS of patients treated and never treated with crizotinib, 19.7 (95% CI 13.6-29.7) and 28 (95% CI 16.4-NR) months, respectively (p = 0.16); mOS of the TKI cohort and of the TKI-naïve patient cohort were 27.1 (95% CI 18-29.7) and 35.6 (95% CI 8.6-NR) months respectively, with no significant difference (p = 0.7).

Conclusions: In this real-life study, there was no evidence of benefit in mOS with anti-MET TKIs.

PubMed Disclaimer

References

    1. Reungwetwattana T, Liang Y, Zhu V, Ou S-HI. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: the why, the how, the who, the unknown, and the inevitable. Lung Cancer. 2017;103:27–37. - DOI - PubMed
    1. Vuong HG, Ho ATN, Altibi AMA, Nakazawa T, Katoh R, Kondo T. Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer—a systematic review and meta-analysis. Lung Cancer. 2018;123:76–82. - DOI - PubMed
    1. Duplaquet L, Kherrouche Z, Baldacci S, Jamme P, Cortot AB, Copin M-C, et al. The multiple paths towards MET receptor addiction in cancer. Oncogene. 2018;37:3200–15. - DOI - PubMed
    1. Bylicki O, Paleiron N, Assié J-B, Chouaïd C. Targeting the MET-signaling pathway in non-small-cell lung cancer: evidence to date. OncoTargets Ther. 2020;13:5691–706. - DOI
    1. Comoglio PM, Trusolino L, Boccaccio C. Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy. Nat Rev Cancer. 2018;18:341–58. - DOI - PubMed

Publication types

LinkOut - more resources